Hosomi, Yukako
Munekawa, Chihiro
Hashimoto, Yoshitaka http://orcid.org/0000-0002-8794-0550
Okamura, Takuro
Takahashi, Fuyuko
Kawano, Rena
Nakajima, Hanako
Majima, Saori
Senmaru, Takafumi
Nakanishi, Naoko
Ushigome, Emi
Hamaguchi, Masahide
Yamazaki, Masahiro
Fukui, Michiaki
Article History
Received: 28 January 2021
Accepted: 8 April 2021
First Online: 19 April 2021
Declarations
:
: Michiaki Fukui received honoraria from Sanofi K.K., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corporation., MSD K.K., Takeda Pharmaceutical Company Limited, ONO PHARMACEUTICAL CO., LTD., Taisho Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co. Ltd., AstraZeneca K.K., SANWA KAGAKU KENKYUSHO CO., LTD., Eli Lilly Japan K.K., and KOWA PHARMACEUTICAL COMPANY LTD. and subsidies or received donations from Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, DAIICHI SANKYO COMPANY, LIMITED, Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Company Limited, Sanofi K.K., Novo Nordisk Pharma Ltd., MSD K.K., Eli Lilly Japan K.K., SANWA KAGAKU KENKYUSHO CO., LTD., and Abbott Japan LLC. and received endowed departments by commercial entities from ONO PHARMACEUTICAL CO., LTD. The other authors have nothing to disclose.
: This study was approved by the ethics committee of Kyoto Prefectural University of Medicine (KPUM) (ERB-C-1297, 2018/10/11). This study was opt-out survey and opt-out survey was approved by the ethics committee.
Free to read: This content has been made available to all.